Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 3, 2011, Pages 175-182

  Li, Cheng ^a,c   Lim, Sung Cil ^b   Kim, Jin ^d   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

^b Chungbuk National University   (South Korea)

^c YANBIAN UNIVERSITY   (China)

^d Chonnam National University Medical School   (South Korea)

Author keywords

Bioavailability; CYP subfamily; Metabolite; Myricetin; P gp; Rats; Tamoxifen

Indexed keywords

AFIMOXIFENE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLYCOPROTEIN P; MYRICETIN; TAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CYP2C9 PROTEIN, RAT; CYTOCHROME P 450 3A4, RAT; CYTOCHROME P-450 3A4, RAT; CYTOCHROME P450; DRUG DERIVATIVE; FLAVONOID; RHODAMINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RAT; SMALL INTESTINE; ANIMAL; BIOAVAILABILITY; DRUG ANTAGONISM; DRUG INTERACTION; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ESTROGEN ANTAGONISTS; FLAVONOIDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINES; TAMOXIFEN;

EID: 84856407755     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0036-y     Document Type: Article

References (36)

1. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Price KN, Regan MM, Gelber RD, Coates AS (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New Engl J Med 361:766-776
2. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152 (Pubitemid 32368013)
3. Buckley MM, Goa KL (1989) Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37:451-490
4. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, LennernasH,Zhong Y,AmidonGL,Yu LX, SunD(2006)Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686 (Pubitemid 44200529)
5. Choi DH, Li C, Choi JS (2010) Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol 62:908-914
6. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190 (Pubitemid 27218241)
7. Crewe HK, Ellis SW, Lennard MS, Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178 (Pubitemid 27013472)
8. Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045 (Pubitemid 34165010)
9. Daniel P, Gaskell SJ, Bishop H, Campbell C, Nicholson RI (1981) Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur J Cancer Clin Oncol 17:1183-1189 (Pubitemid 12247998)
10. Dixon RA, Steele CL (1999) Flavonoids and isoflavonoids-a gold mine for metabolic engineering. Trends Plant Sci 4:394-400.
11. Fried KM, Wainer IW (1994) Direct determination of tamoxifen and its four major metabolites in plasma using coupled column highperformance liquid chromatography. J Chromatogr B Biomed Appl 655:261-268 (Pubitemid 24169259)
12. Fukazawa I, Uchida N, Uchida E, Yasuhara H (2004) Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Brit J Clin Pharmacol 57:448-455 (Pubitemid 38519650)
13. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS (1995) In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 133:269-276
14. German JB, Walzem RL (2000) The health benefits of wine. Annu Rev Nutr 20:561-593
15. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060 (Pubitemid 17204301)
16. Hakkinen SH, Karenlampi SO, Heinonen IM, Mykkanen HM, Torronen AR (1999) Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem 47:2274-2279. (Pubitemid 29325110)
17. Han CY, Cho KB, Choi HS, Han HK, Kang KW (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29:1837-1844
18. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919
19. Jordan VC (1989) Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Brit J Clin Pharmacol 110:507-517 (Pubitemid 23279253)
20. Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316 (Pubitemid 8219148)
21. Kaminsky LS, Fasco MJ (1991) Small intestinal cytochromes P450. Crit Rev Toxicol 21:407-422
22. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24:321-328 (Pubitemid 30342700)
23. Kim CS, Choi SJ, Park CY, Li C, Choi JS (2010) Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 30:79-85
24. Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G (2005) Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein- mediated transport in KB-C2 cells. Biol Pharm Bull 28:2274-2278 (Pubitemid 41757420)
25. Lewis DFV (1996) Cytochrome P450. Substrate specificity and metabolism. In: Lewis DFV (ed) Cytochromes P450. Structure, function, and mechanism. Taylor & Francis, Bristol, pp 122-123
26. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A (2006) Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66:4410-4418
27. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21:645-656 (Pubitemid 23221760)
28. Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751
29. Rao US, Fine RL, Scarborough GA (1994) Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48:287-292
30. Shin SC, Choi JS (2009) Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs 20:584-588
31. Shin SC, Piao YJ, Choi JS (2008) Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. In Vivo 22:391-395
32. Sutherland L, Ebner T, Burchell B (1993) The expression of UDPglucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45: 295-301 (Pubitemid 23042627)
33. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787 (Pubitemid 32222427)
34. von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ (2004) Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56:1039-1044 (Pubitemid 39140060)
35. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134
36. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443